Market research
LMNL.TO Liminal BioSciences Inc
TO CAD Healthcare
Latest close
As of 29 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 540M
- P/E ratio
- 1.28
- Analyst target
- 21
- Dividend yield
- Not available
- Beta
- 1.81
Profile
Instrument facts
- Exchange
- TO
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA53272L1031
- Market cap
- 540M
- P/E ratio
- 1.28
- Analyst target
- 21
- Dividend yield
- Not available
- Beta
- 1.81
About
About Liminal BioSciences Inc
Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on discovery, development, and commercialization of novel treatments for patients suffering from diseases that have unmet medical needs. It operates through two segments, Small Molecule Therapeutics and Plasma Derived Therapeutics. The Small Molecule Therapeutics segment's lead product candidate is fezagepras (PBI-4050) for the treatment of idiopathic pulmonary fibrosis, respiratory diseases, and Alström Syndrome. The Plasma Derived Therapeutics segment provides Plasma Protein Purification System, a multi-product sequential purification process for the extraction and purification of therapeutic proteins from human plasma. It also engages in developing Ryplazim for the treatment of congenital plasminogen deficiency. The company operates in Canada, the United Kingdom, and the United States. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.
Research context
Liminal BioSciences Inc appears in PyInvesting’s Toronto Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the LMNL.TO discussion.
5 years, 6 months ago
Liminal BioSciences Inc is currently in a long term downtrend where the price is trading 21.0% below its 200 day moving average.
From a valuation standpoint, the stock is 87.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 132.4.
Liminal BioSciences Inc's total revenue sank by 87.9% to $639K since the same quarter in the previous year.
Its net income has increased by 22.0% to $-23M since the same quarter in the previous year.
Finally, its free cash flow fell by 0.9% to $-18M since the same quarter in the previous year.
Based on the above factors, Liminal BioSciences Inc gets an overall score of 2/5.